CN108578413A - 包含短效苯二氮杂*类化合物的组合物 - Google Patents

包含短效苯二氮杂*类化合物的组合物 Download PDF

Info

Publication number
CN108578413A
CN108578413A CN201810206738.1A CN201810206738A CN108578413A CN 108578413 A CN108578413 A CN 108578413A CN 201810206738 A CN201810206738 A CN 201810206738A CN 108578413 A CN108578413 A CN 108578413A
Authority
CN
China
Prior art keywords
composition
lyophilized
lactose
composition according
dextran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810206738.1A
Other languages
English (en)
Chinese (zh)
Inventor
J·A·格雷厄姆
A·J·拜利尔
K·R·沃德
T·皮考克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paion UK Ltd
Original Assignee
Paion UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48669863&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN108578413(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Paion UK Ltd filed Critical Paion UK Ltd
Publication of CN108578413A publication Critical patent/CN108578413A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201810206738.1A 2012-05-22 2013-05-22 包含短效苯二氮杂*类化合物的组合物 Pending CN108578413A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12168968.1 2012-05-22
EP12168968 2012-05-22
CN201380036582.2A CN104968348B (zh) 2012-05-22 2013-05-22 包含短效苯二氮杂*类化合物的组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380036582.2A Division CN104968348B (zh) 2012-05-22 2013-05-22 包含短效苯二氮杂*类化合物的组合物

Publications (1)

Publication Number Publication Date
CN108578413A true CN108578413A (zh) 2018-09-28

Family

ID=48669863

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810206738.1A Pending CN108578413A (zh) 2012-05-22 2013-05-22 包含短效苯二氮杂*类化合物的组合物
CN201380036582.2A Active CN104968348B (zh) 2012-05-22 2013-05-22 包含短效苯二氮杂*类化合物的组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380036582.2A Active CN104968348B (zh) 2012-05-22 2013-05-22 包含短效苯二氮杂*类化合物的组合物

Country Status (41)

Country Link
US (2) US20150148338A1 (https=)
EP (1) EP2852389B1 (https=)
JP (1) JP6313286B2 (https=)
KR (1) KR102116737B1 (https=)
CN (2) CN108578413A (https=)
AP (1) AP2014008084A0 (https=)
AR (1) AR092008A1 (https=)
AU (1) AU2013265295B2 (https=)
BR (1) BR112014029108B1 (https=)
CA (1) CA2874247C (https=)
CL (1) CL2014003171A1 (https=)
CO (1) CO7151503A2 (https=)
DK (1) DK2852389T3 (https=)
EA (1) EA032119B1 (https=)
EC (1) ECSP14032553A (https=)
ES (1) ES2651389T3 (https=)
FR (1) FR21C1043I2 (https=)
GE (2) GEAP201813666A (https=)
HR (1) HRP20171872T1 (https=)
HU (2) HUE037734T2 (https=)
IL (1) IL235789B (https=)
LT (2) LT2852389T (https=)
LU (1) LUC00230I2 (https=)
MA (1) MA37581B1 (https=)
MX (1) MX368854B (https=)
MY (1) MY185117A (https=)
NL (1) NL301130I2 (https=)
NO (2) NO2852389T3 (https=)
NZ (1) NZ702063A (https=)
PE (1) PE20150683A1 (https=)
PH (1) PH12014502608B1 (https=)
PL (1) PL2852389T4 (https=)
PT (1) PT2852389T (https=)
RS (1) RS56660B1 (https=)
SG (1) SG11201407710VA (https=)
SI (1) SI2852389T1 (https=)
TN (1) TN2014000479A1 (https=)
TW (1) TWI590826B (https=)
UA (1) UA115063C2 (https=)
WO (1) WO2013174883A1 (https=)
ZA (1) ZA201408412B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112209932A (zh) * 2019-07-12 2021-01-12 成都倍特药业股份有限公司 一种化合物氢溴酸盐的新固体形态及其制备方法和用途
CN112462015A (zh) * 2020-11-18 2021-03-09 海南倍特药业有限公司 一种氢溴酸瑞马唑仑细菌内毒素的检测方法

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2657347C (en) 2006-07-10 2014-11-18 Paion Uk Limited Short-acting benzodiazepine salts and their polymorphic forms
EP2305647A1 (en) 2009-09-18 2011-04-06 PAION UK Limited Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
WO2015076340A1 (ja) * 2013-11-21 2015-05-28 小野薬品工業株式会社 全身麻酔および／または鎮静のための注射用組成物
ES2958606T3 (es) 2014-02-10 2024-02-12 Biolumic Ltd Mejoras en y relacionadas con el control de características de organismos fotosintéticos
JP6697806B2 (ja) 2014-03-14 2020-05-27 バイオルミック リミテッド 作物の収量及び／又は品質を改善する方法
HUE047450T2 (hu) 2014-07-23 2020-04-28 Jiangsu Nhwaluokang Pharmaceutical Res And Development Co Ltd Új benzodiazepin származék és alkalmazása
EP4091440A1 (en) 2014-09-17 2022-11-23 Biolumic Limited Method of seed treatments and resulting products
CN105726495B (zh) * 2014-12-12 2019-03-29 宜昌人福药业有限责任公司 一种注射用短效苯并二氮杂卓盐药物组合物及其制备方法
CN107198691A (zh) * 2016-03-17 2017-09-26 江苏恒瑞医药股份有限公司 一种瑞马唑仑的药物组合物
EP3442539B1 (en) * 2016-04-14 2025-04-09 Paion UK Limited Orally inhaled and nasal benzodiazepines
CN108289897B (zh) * 2016-05-20 2020-07-28 江苏恒瑞医药股份有限公司 一种瑞马唑仑的药物组合物
CA3034739A1 (en) 2016-08-22 2018-03-01 Biolumic Limited System, device and methods of seed treatment
CN108503644B (zh) 2016-12-09 2019-06-14 成都倍特药业有限公司 一种苯并二氮杂*衍生物的氢溴酸盐及其制备方法和用途
WO2019002946A1 (en) 2017-06-29 2019-01-03 Biolumic Limited METHOD OF ENHANCING YIELD AND / OR CULTURE QUALITY
EP3714884A1 (en) 2019-03-27 2020-09-30 Paion UK Limited Medical uses for benzodiazepines with a particular eeg pattern
ES2803099B2 (es) * 2019-07-22 2021-11-08 Moehs Iberica Sl Procedimiento de obtención de besilato de remimazolam amorfo
CN114478535B (zh) * 2020-10-23 2024-02-09 成都苑东生物制药股份有限公司 一种苯磺酸瑞马唑仑ii晶型的制备方法
CN114624351B (zh) * 2020-12-14 2024-04-09 宜昌人福药业有限责任公司 苯磺酸瑞马唑仑原料药中(r)-(-)-1-氨基-2-丙醇残留的分析方法
AU2023394304A1 (en) * 2022-12-16 2025-05-22 Lts Lohmann Therapie-Systeme Ag Oromucosal delivery system containing remimazolam
EP4711368A1 (en) * 2023-06-09 2026-03-18 Chengdu Mfs Pharma. Co., Ltd. Azepine compound, and composition and use thereof
WO2025052259A1 (en) 2023-09-05 2025-03-13 Reena Patel Ready to use compositions of remimazolam

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3520877A (en) * 1967-10-02 1970-07-21 Hoffmann La Roche 3-carbonyl amino acetic acid ethyl ester substituted benzodiazepines
CN1345725A (zh) * 2000-06-09 2002-04-24 沃尼尔·朗伯公司 治疗慢性阻塞性肺部疾病的二氮杂䓬并吲哚
WO2008007081A1 (en) * 2006-07-10 2008-01-17 Cenes Limited Short-acting benzodiazepine salts and their polymorphic forms
CN101501019A (zh) * 2006-07-10 2009-08-05 Paion英国有限公司 短效苯并二氮杂盐及其多晶型
CN102781943A (zh) * 2009-11-05 2012-11-14 葛兰素史密丝克莱恩有限责任公司 苯并二氮杂*溴结构域抑制剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2143246C (en) 1994-03-16 2000-08-22 Thierry Godel Imidazodiazepines
PT801651E (pt) 1995-01-06 2001-12-28 Hoffmann La Roche Hidroximetil-imidazodiazepinas e seus esteres
AU4382896A (en) 1995-02-02 1996-08-21 F. Hoffmann-La Roche Ag Acetylimidazobenzodiazepines
JPH0971533A (ja) * 1995-06-30 1997-03-18 Takeda Chem Ind Ltd 凍結乾燥製剤
GB9911152D0 (en) * 1999-05-14 1999-07-14 Glaxo Group Ltd Short-acting benzodiazepines
US7160880B1 (en) * 1999-05-14 2007-01-09 Cenes Limited Short-acting benzodiazepines
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
MX2007009915A (es) * 2005-02-15 2007-11-06 Elan Pharma Int Ltd Formulaciones en aerosol e inyectables de benzodiazepina nanoparticulada.
CA2657347C (en) * 2006-07-10 2014-11-18 Paion Uk Limited Short-acting benzodiazepine salts and their polymorphic forms
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
EP2450039A1 (en) * 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
CN102964349A (zh) * 2011-08-31 2013-03-13 江苏恒瑞医药股份有限公司 苯并二氮杂*衍生物的托西酸盐及其多晶型、它们的制备方法和用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3520877A (en) * 1967-10-02 1970-07-21 Hoffmann La Roche 3-carbonyl amino acetic acid ethyl ester substituted benzodiazepines
CN1345725A (zh) * 2000-06-09 2002-04-24 沃尼尔·朗伯公司 治疗慢性阻塞性肺部疾病的二氮杂䓬并吲哚
WO2008007081A1 (en) * 2006-07-10 2008-01-17 Cenes Limited Short-acting benzodiazepine salts and their polymorphic forms
CN101501019A (zh) * 2006-07-10 2009-08-05 Paion英国有限公司 短效苯并二氮杂盐及其多晶型
CN102781943A (zh) * 2009-11-05 2012-11-14 葛兰素史密丝克莱恩有限责任公司 苯并二氮杂*溴结构域抑制剂

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANKET BAHETI ET AL.: "Excipients used in lyophilization of small molecules", 《J.EXCIPIENTS AND FOOD CBEM.》 *
GREGORY J.PACOFSKY ET AL.: "Relating the Structure,Activity,and Physical Properties of Ultrashort-Acting Benzodiazepine Receptor Agonists", 《BIOORGANIC & MEDICINAL CHEMISITRY LETTERS》 *
JEFFREY A.STAFFORD ET AL.: "Identification and Structure-Activity Studies of Novel Ultrashort-Acting Benzodiazepine Receptor Agonists", 《BIOORGANIC & MEDICINAL CHEMISITRY LETTERS》 *
姚静等: "《药物冻干制剂技术的设计及应用》", 30 June 2007, 中国医药科技出版社 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112209932A (zh) * 2019-07-12 2021-01-12 成都倍特药业股份有限公司 一种化合物氢溴酸盐的新固体形态及其制备方法和用途
CN112462015A (zh) * 2020-11-18 2021-03-09 海南倍特药业有限公司 一种氢溴酸瑞马唑仑细菌内毒素的检测方法
CN112462015B (zh) * 2020-11-18 2022-07-12 海南倍特药业有限公司 一种氢溴酸瑞马唑仑细菌内毒素的检测方法

Also Published As

Publication number Publication date
KR102116737B1 (ko) 2020-05-29
DK2852389T3 (en) 2017-12-18
GEAP201813666A (en) 2018-01-25
JP6313286B2 (ja) 2018-04-18
HUE037734T2 (hu) 2018-09-28
EA032119B1 (ru) 2019-04-30
NO2021041I1 (no) 2021-09-20
US20220040198A1 (en) 2022-02-10
WO2013174883A1 (en) 2013-11-28
LT2852389T (lt) 2017-12-27
RS56660B1 (sr) 2018-03-30
HRP20171872T1 (hr) 2018-02-23
PT2852389T (pt) 2017-12-13
AP2014008084A0 (en) 2014-11-30
CL2014003171A1 (es) 2015-06-19
AR092008A1 (es) 2015-03-18
SG11201407710VA (en) 2015-01-29
SI2852389T1 (en) 2018-02-28
LTC2852389I2 (https=) 2024-11-25
MA37581B1 (fr) 2016-07-29
AU2013265295A1 (en) 2015-01-22
IL235789A0 (en) 2015-01-29
PH12014502608A1 (en) 2015-01-21
TWI590826B (zh) 2017-07-11
JP2015517552A (ja) 2015-06-22
KR20150009601A (ko) 2015-01-26
EP2852389B1 (en) 2017-10-18
US20150148338A1 (en) 2015-05-28
CA2874247C (en) 2020-07-28
NO2852389T3 (https=) 2018-03-17
MX368854B (es) 2019-10-18
FR21C1043I2 (fr) 2022-10-07
LTPA2021521I1 (https=) 2021-10-11
PH12014502608B1 (en) 2019-11-27
EA201492160A1 (ru) 2015-10-30
IL235789B (en) 2019-07-31
UA115063C2 (uk) 2017-09-11
ZA201408412B (en) 2016-09-28
ECSP14032553A (es) 2018-11-30
PE20150683A1 (es) 2015-06-03
EP2852389A1 (en) 2015-04-01
TW201400119A (zh) 2014-01-01
HUS2100040I1 (hu) 2021-10-28
LUC00230I2 (https=) 2022-10-07
GEP20186852B (en) 2018-05-25
NL301130I2 (nl) 2021-10-25
CO7151503A2 (es) 2014-12-29
MX2014014225A (es) 2015-06-17
PL2852389T3 (pl) 2018-02-28
CA2874247A1 (en) 2013-11-28
CN104968348B (zh) 2018-04-17
HK1208164A1 (en) 2016-02-26
TN2014000479A1 (en) 2016-03-30
FR21C1043I1 (https=) 2021-11-19
MY185117A (en) 2021-04-30
BR112014029108B1 (pt) 2022-02-08
NL301130I1 (https=) 2021-09-22
BR112014029108A2 (pt) 2017-06-27
MA20150233A1 (fr) 2015-07-31
NZ702063A (en) 2016-11-25
AU2013265295B2 (en) 2017-08-31
ES2651389T3 (es) 2018-01-26
PL2852389T4 (pl) 2022-02-21
CN104968348A (zh) 2015-10-07

Similar Documents

Publication Publication Date Title
CN104968348B (zh) 包含短效苯二氮杂*类化合物的组合物
JP5380549B2 (ja) ボリコナゾール含有の薬物製剤及びその調製方法
JP6869941B2 (ja) ある含有量のマイトマイシンｃを有する凍結乾燥医薬組成物を製造する方法
TW200944508A (en) Novel solid forms of bendamustine hydrochloride
ES2573982T3 (es) Proceso para la producción de coevaporados y complejos que comprenden voriconazol y ciclodextrina
CN101953832B (zh) β-环糊精包合依达拉奉的口服药物组合物及其制备方法
WO2022109050A1 (en) Complexing agent salt formulations of pharmaceutical compounds
JP6182262B2 (ja) 抗がん剤を含む安定な水溶性医薬組成物
US20260014190A1 (en) Complexing agent salt formulations of pharmaceutical compounds
CN104844600A (zh) 一种他达拉非化合物、及其组合物
CA2894935A1 (en) Novel crystalline forms of ceftaroline fosamil
JP7148642B2 (ja) 安定したアザシチジン含有医薬組成物の製造方法
CN108289897B (zh) 一种瑞马唑仑的药物组合物
HK1208164B (en) Compositions comprising short-acting benzodiazepines
OA20108A (en) Compositions Comprising Short-Acting Benzodiazepines.
CN111100122A (zh) 左旋四氢帕马丁新化合物
BR112021013764B1 (pt) Método de preparação de uma composição farmacêutica compreendendo acetaminofeno e nefopa
BR112021013764A2 (pt) Método de fabricação de uma composição farmacêutica que compreende nefopam e acetaminofeno, e a composição farmacêutica assim obtida
EP2976067A1 (en) Pharmaceutical composition comprising a fluoroquinolone antibacterial agent and method for the preparation thereof
TW200403064A (en) Pharmaceutical composition for injection of cefem compound

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180928

WD01 Invention patent application deemed withdrawn after publication